Jay B. Lichter - 10 Jun 2021 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director, 10%+ Owner
Signature
/s/ Tighe Reardon, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
10 Jun 2021
Net transactions value
$0
Form type
4
Filing time
14 Jun 2021, 17:37:42 UTC
Next filing
16 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 10 Jun 2021 Common Stock 30,000 $17.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest in equal monthly installments over the 36 months following June 10, 2021.